COMPANY

Alpheus Medical

HQ: Chanhassen, MN source · alpheusmedical.com ↗ · Midwest

Alpheus is developing a non-invasive therapy that uses a tumor-accumulating drug together with low-intensity ultrasound to create localized activity inside the brain. From company website Source · Oct 12, 2026

Keywords: GBM Glioblastoma Glioblastom WHO Grade 4 bGBM Butterfly GBM Bihemispheric GBM High Grade Glioma CV01-delivered ultrasound

Location: Chanhassen, MN · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Raises and deals from press releases

Raise Series B · $52M · announced May 15, 2025 Company release ↗
Source quote
- May 15, 2025 · Company release ↗
  “CHANHASSEN, Minn., May 15, 2025 — Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the closing of an oversubscribed $52 million Series B financing round”

Raises announced in these releases: $52M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Oct 29, 2026 Trial start Phase 1: TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma source ↗
Jan 28, 2026 Trial start Phase 2: Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma source ↗
May 15, 2025 Raise Series B · $52M source ↗
Jun 29, 2022 Trial start Phase 1: Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma source ↗

Upcoming milestones

Oct 30, 2027 (ESTIMATED) · Phase 1 · TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma · NCT07862647
2027-12 (ESTIMATED) · Phase 2 · Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma · NCT07225621

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07862647	TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma	Phase 1	Recruiting	Oct 29, 2026	Oct 30, 2027 (estimated)
NCT07225621	Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma	Phase 2	Recruiting	Jan 28, 2026	2027-12 (estimated)
NCT05362409	Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma	Phase 1	Completed	Jun 29, 2022	Dec 3, 2024 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗